BCL11A erythroid enhancer

The BCL11A erythroid enhancer is a specific DNA regulatory region within intron-2 of the BCL11A gene that ensures expression of BCL11A during erythroid development, enabling the switch from fetal (γ-globin/HbF) to adult (β-globin/HbA) hemoglobin. Disrupting (editing) this enhancer leads to selective derepression of fetal globin genes and increased HbF production in red blood cells—a strategy used to treat hemoglobinopathies. Unlike global inhibition of BCL11A, enhancing editing spares the essential functions of BCL11A in other tissues, improving safety. Genome-wide association studies and functional validations have established the enhancer as a highly attractive therapeutic target for gene editing approaches in sickle cell disease and beta-thalassemia, with robust efficacy demonstrated in preclinical and clinical models

Other names

BCL11A +58 erythroid enhancerBCL11A intronic erythroid enhancer

disruption (deletion or editing) increases γ-globin/fetal hemoglobin (HbF) synthesis by silencing BCL11A in erythroid cells\nrestores globin chain balance in erythroid precursors\nspares BCL11A's functions in non-erythroid tissues, reducing off-target effects